Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$1.11
$0.99
$0.65
$1.75
$66.22M-0.02517,896 shs51,272 shs
OS Therapies Inc stock logo
OSTX
OS Therapies
$1.66
+0.2%
$1.78
$1.12
$7.00
$46.50MN/A490,361 shs86,089 shs
Nuvilex Inc. stock logo
PMCB
Nuvilex
$1.11
+1.3%
$1.07
$1.00
$2.42
$7.55M-0.4219,625 shs7,872 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.41
+3.9%
$0.75
$0.30
$4.28
$19.44M-0.061.37 million shs572,245 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
+4.72%+12.12%+5.71%+55.51%+110,999,900.00%
OS Therapies Inc stock logo
OSTX
OS Therapies
+2.47%-13.09%-16.16%+48.21%+165,999,900.00%
Nuvilex Inc. stock logo
PMCB
Nuvilex
+0.91%-1.77%+6.73%-2.63%-45.32%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+3.53%+1.27%-53.86%-32.74%-67.51%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
1.493 of 5 stars
3.50.00.00.01.20.00.6
OS Therapies Inc stock logo
OSTX
OS Therapies
2.6215 of 5 stars
3.70.00.00.02.31.70.6
Nuvilex Inc. stock logo
PMCB
Nuvilex
0.8946 of 5 stars
0.03.00.00.00.60.81.9
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
2.4551 of 5 stars
3.61.00.00.01.13.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
3.00
Buy$7.33560.66% Upside
OS Therapies Inc stock logo
OSTX
OS Therapies
3.40
Buy$18.00984.34% Upside
Nuvilex Inc. stock logo
PMCB
Nuvilex
0.00
N/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
3.29
Buy$9.002,208.28% Upside

Current Analyst Ratings Breakdown

Latest PMCB, RVPH, OSTX, and IRD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/27/2025
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/27/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
6/24/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/9/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/3/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
5/20/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $3.00
5/15/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/24/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/22/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/11/2025
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$10.99M6.03N/AN/A$0.21 per share5.29
OS Therapies Inc stock logo
OSTX
OS Therapies
N/AN/AN/AN/AN/AN/A
Nuvilex Inc. stock logo
PMCB
Nuvilex
N/AN/AN/AN/A$3.27 per shareN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$0.02 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
-$57.53M-$2.10N/AN/AN/A-429.42%-283.28%-144.32%8/12/2025 (Estimated)
OS Therapies Inc stock logo
OSTX
OS Therapies
-$7.79M-$0.86N/AN/AN/AN/AN/A-569.57%N/A
Nuvilex Inc. stock logo
PMCB
Nuvilex
$330K$0.741.50N/AN/A0.51%0.35%8/11/2025 (Estimated)
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$29.92M-$0.79N/AN/AN/AN/AN/A-302.31%8/13/2025 (Estimated)

Latest PMCB, RVPH, OSTX, and IRD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
-$0.34-$0.32+$0.02-$0.24$4.00 million$4.30 million
5/15/2025Q1 2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.21-$0.13+$0.08-$0.13N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
N/AN/AN/AN/AN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
N/AN/AN/AN/AN/A
Nuvilex Inc. stock logo
PMCB
Nuvilex
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
N/A
1.98
1.98
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A
0.76
0.76
Nuvilex Inc. stock logo
PMCB
Nuvilex
N/A
14.21
14.21
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
0.54
0.54

Institutional Ownership

CompanyInstitutional Ownership
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
14.97%
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A
Nuvilex Inc. stock logo
PMCB
Nuvilex
34.24%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%

Insider Ownership

CompanyInsider Ownership
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
6.60%
OS Therapies Inc stock logo
OSTX
OS Therapies
13.80%
Nuvilex Inc. stock logo
PMCB
Nuvilex
10.20%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
27.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
1459.66 million55.72 millionN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A28.10 millionN/AN/A
Nuvilex Inc. stock logo
PMCB
Nuvilex
46.86 million6.16 millionOptionable
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
548.00 million34.96 millionOptionable

Recent News About These Companies

Reviva Dives on Stock Offering
RVPH: M&A Deals Highlight Brilaroxazine Value

New MarketBeat Followers Over Time

Media Sentiment Over Time

Opus Genetics stock logo

Opus Genetics NASDAQ:IRD

$1.11 0.00 (0.00%)
As of 10:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

OS Therapies stock logo

OS Therapies NYSE:OSTX

$1.66 +0.00 (+0.24%)
As of 10:27 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Nuvilex stock logo

Nuvilex NASDAQ:PMCB

$1.11 +0.01 (+1.27%)
As of 10:28 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.40 +0.02 (+3.87%)
As of 10:31 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.